Porton Advanced Secures China NMPA Drug License to Expand CDMO Services to Commercial CGT Manufacturing

August 17, 2026

Porton Advanced China

Overview

Porton Advanced has been granted a Class C Drug Manufacturing License by China’s NMPA, enabling it to undertake commercial contract manufacturing for Cell and Gene Therapy (CGT) products. This expands their CDMO services to cover the full spectrum from process development and clinical production to commercialization. The company’s facilities include 10 viral vector production lines and 12 GMP cell therapy suites, with 2 dedicated to commercial production, addressing the surging demand for CGT manufacturing. This license is a critical milestone for accelerating CGT product market entry in China.

In Depth

Key Findings

Porton Advanced has announced that it has been granted a Class C Drug Manufacturing License by China’s National Medical Products Administration (NMPA), enabling the company to officially engage in commercial contract development and manufacturing (CDMO) for Cell and Gene Therapy (CGT) products. This pivotal authorization significantly broadens Porton Advanced’s service offerings, extending them from process development and clinical production to full-scale commercial manufacturing.

Technical / Clinical Details

The company’s advanced manufacturing facilities are equipped with 10 viral vector production lines and 12 GMP-compliant cell therapy suites. Notably, two of these GMP suites are specifically dedicated to commercial production, ensuring the capacity to handle large-scale and high-quality CGT product manufacturing. The Class C license represents one of the highest levels of drug manufacturing permits in China, underscoring Porton Advanced’s capability to deliver top-tier CDMO services across the entire lifecycle of CGT products. Their comprehensive service suite includes cell line development, process optimization, analytical method development, quality control testing, and regulatory filing support.

Background & Context

The cell and gene therapy sector is experiencing rapid global expansion, with China being a significant player in this growth. While numerous innovative CGT products are advancing through clinical development, the transition to commercial production demands highly sophisticated technology, stringent quality control, and strict adherence to regulatory requirements. In the Chinese market, meeting the NMPA’s rigorous regulatory standards has historically posed a substantial barrier to product commercialization. Porton Advanced’s acquisition of this license directly addresses this challenge, providing essential infrastructure for domestic CGT developers to efficiently bring their products to market.

Strategic Significance & Outlook

This commercial manufacturing license represents a transformative moment for Porton Advanced and a significant strengthening of the CGT industry’s supply chain in China. The company is now well-positioned to meet the escalating manufacturing demands from both domestic and international CGT developers, thereby accelerating pipeline progression and improving patient access to these life-changing therapies. Moving forward, it is anticipated that more CGT products will enter the Chinese market, benefiting patients with innovative treatment options. Porton Advanced plans to continue optimizing its production capabilities and driving technological innovation, all while upholding stringent cGMP standards, to solidify its leadership in the industry.

Source: https://www.portonadvanced.com/porton-advanced-drug-manufacturing-license-cdmo/

Get our weekly technology intelligence — free

Receive an infographic that lets you judge at a glance whether each field’s analysis report is worth reading.

Subscribe Free — Weekly Tech Intelligence

By subscribing, you’ll receive Troy-Technical’s weekly technology intelligence newsletter.